Musculo-skeletal disorders, Medicines planning
9 results
Applied filters
Preparing to use golimumab biosimilar
9 January 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
The licence and supporting evidence for denosumab 60mg biosimilars
17 December 2025Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for tocilizumab biosimilar
1 September 2025One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
Good governance when implementing tocilizumab biosimilar
1 August 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
Preparing to use tocilizumab biosimilar
1 August 2025Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.